Novo’s Wegovy pill is planned to enter U.S. self-pay channels, Reuters says

TipRanks

Wed, December 24, 2025 astatine 5:25 AM CST 1 min read

Novo Nordisk’s (NVO) recently approved mentation of Wegovy is planned to spell consecutive to U.S. self-pay channels successful aboriginal January, Maggie Fick of Reuters reports. As portion of the company’s woody with the Trump medication successful November, Novo and Lilly (LLY) agreed to merchantability starter doses of their weight-loss pills for $149 a period to U.S. Medicare and Medicaid patients arsenic good arsenic cash-paying customers without security coverage. The pill volition service arsenic a trial lawsuit for the cash-paying user market.

Claim 70% Off TipRanks This Holiday Season

• Unlock hedge-fund level information and almighty investing tools for smarter, sharper decisions

• Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected NVO:

Disclaimer & DisclosureReport an Issue

• Novo Nordisk Stock (NVO) Pops arsenic FDA Approves Wegovy Weight Loss Pill

• Closing Bell Movers: Novo Nordisk gains connected Wegovy FDA update

• Novo Nordisk says Wegovy pill approved successful U.S. arsenic oral GLP-1, Bloomberg reports

• Novo Nordisk says FDA approved Wegovy pill to trim assemblage weight

• Novo Nordisk up 8% astatine $51.79 aft FDA support of Wegovy successful value loss